Regeneron Pharmaceuticals 2024 Financial Highlights
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) has unveiled its financial results for the fourth quarter and full year 2024, showcasing remarkable growth and a strong commitment to its shareholders. The fourth quarter revenues rose by an impressive 10%, reaching $3.79 billion compared to the same period last year.
Full Year Financial Overview
The company reported full year revenues of $14.20 billion, marking an 8% increase from 2023. When excluding the impact of Ronapreve, the revenue increase was even more significant at 10%. This growth trajectory highlights Regeneron's resilience and the robust demand for its flagship products.
Quarterly Sales Update
Record Sales for Dupixent
One of the standout performers was Dupixent, with global net sales recorded by Sanofi jumping 15% to $3.70 billion in the fourth quarter, while full year sales reached $14.15 billion, up 22% from 2023. This figure underscores Dupixent's pivotal role in Regeneron's portfolio, firmly establishing it as a leader in the treatment of various allergic and inflammatory conditions.
EYLEA Performance
Sales of EYLEA continued to show stability with U.S. net sales for both EYLEA HD and EYLEA increasing 2% compared to last year to reach $1.50 billion in Q4. The total sales for the fiscal year were reported at $5.97 billion, a 1% increase from 2023. EYLEA HD, a newer addition to the lineup, contributed significantly to this revenue growth, indicating successful market penetration and acceptance.
Libtayo and Other Treatments
The fourth quarter also saw Libtayo's global net sales swell by 50% to $367 million, and annual sales reached $1.22 billion, representing a 40% increase year-over-year. This strong performance in oncology reflects Regeneron’s ongoing commitment to addressing critical unmet medical needs.
Dividend Announcement and Share Repurchase Program
As part of its shareholder return strategy, Regeneron announced the initiation of a quarterly cash dividend program with a declared amount of $0.88 per share. In addition, the company has authorized a new share repurchase program worth $3.0 billion, augmenting its total buyback capacity to approximately $4.5 billion. This move demonstrates Regeneron's robust financial health and commitment to providing value to its investors.
Regulatory and R&D Advances
Regeneron is making strides with several regulatory applications, including those for EYLEA HD pre-filled syringes, Dupixent for treating bullous pemphigoid, and other promising treatments for various cancers. Notably, significant positive Phase 3 results have been reported for both EYLEA HD and Libtayo in clinical settings.
Upcoming Milestones
Looking ahead, Regeneron has a considerable number of anticipated milestones for 2025. These include submissions for the supplemental Biologics License Applications (sBLA) for multiple indications associated with its key products, reflecting a sustained focus on delivering advanced treatments to patients.
Frequently Asked Questions
What were Regeneron’s revenue figures for 2024?
Regeneron reported total revenues of $14.20 billion for the year 2024, showcasing an 8% increase from 2023.
How did Dupixent perform in the last quarter?
Dupixent achieved global net sales of $3.70 billion in the fourth quarter, a 15% increase compared to the same quarter in 2023.
Is there a dividend for Regeneron shareholders?
Yes, Regeneron declared a quarterly cash dividend of $0.88 per share starting in 2025.
What is the future outlook for Regeneron’s products?
Regeneron is actively working on several new indications and has regulatory applications in progress for various therapies. The company anticipates significant milestones in 2025.
Where can investors find more information on Regeneron?
For more details, investors can visit Regeneron's official website and its investor relations page for updates and further information.
